{"id":"nicotine-delivered-via-an-e-cigarette","safety":{"commonSideEffects":[{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nicotine dependence"}]},"_chembl":{"chemblId":"CHEMBL3989563","moleculeType":"Small molecule","molecularWeight":"498.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicotine crosses the blood-brain barrier and binds to nicotinic acetylcholine receptors, particularly α4β2 subtypes, leading to dopamine release and stimulation of the reward pathway. This mechanism underlies both its addictive properties and potential therapeutic effects on cognition, attention, and mood. When delivered via e-cigarette, nicotine is inhaled and rapidly absorbed through the lungs, providing quick onset of action similar to combustible cigarettes but without tobacco combustion byproducts.","oneSentence":"Nicotine acts as a nicotinic acetylcholine receptor agonist, binding to and activating these receptors in the central and peripheral nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:58.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation aid"},{"name":"Reduction of cigarette consumption in smokers unwilling or unable to quit"}]},"trialDetails":[{"nctId":"NCT04218708","phase":"NA","title":"Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-06-17","conditions":"Nicotine Addiction","enrollment":64},{"nctId":"NCT05311085","phase":"PHASE3","title":"Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2022-05-05","conditions":"Smoking Cessation","enrollment":807},{"nctId":"NCT03575468","phase":"NA","title":"Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes","status":"COMPLETED","sponsor":"Consumer Wellness Solutions","startDate":"2018-05-07","conditions":"Smoking Cessation","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brand name: UpOx"],"phase":"phase_3","status":"active","brandName":"Nicotine delivered via an e-cigarette","genericName":"Nicotine delivered via an e-cigarette","companyName":"University of Auckland, New Zealand","companyId":"university-of-auckland-new-zealand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicotine acts as a nicotinic acetylcholine receptor agonist, binding to and activating these receptors in the central and peripheral nervous system. Used for Smoking cessation aid, Reduction of cigarette consumption in smokers unwilling or unable to quit.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}